Key result
SOD augmentation regresses experimental PAH driven by epigenetic SOD2 deficiency.
Why the study?
Tissue-specific, epigenetic SOD2 deficiency initiates and sustains a heritable form of PAH by impairing redox signaling and creating a proliferative, apoptosis-resistant PASMC.
Does SOD augmentation regress experimental PAH in preclinical models?
Does SOD augmentation regress experimental PAH in preclinical models?
Epigenetic SOD2 deficiency contributes to PAH pathogenesis, and SOD augmentation can regress experimental PAH, highlighting a potential new therapeutic target.
Answers are grounded in this paper and cite their sources.
Does not alter heritable PAH management; hypothesis-generating for epigenetic SOD2-targeted therapies pending clinical validation.
Tissue-specific, epigenetic SOD2 deficiency initiates and sustains a heritable form of PAH by impairing redox signaling and creating a proliferative, apoptosis-resistant PASMC. SOD augmentation regresses experimental PAH. The discovery of an epigenetic component to PAH may offer new therapeutic targets.
No takes yet. Share an insight, caveat, or question.
Archer et al. (2010) studied this question. Epigenetic SOD2 deficiency initiates and sustains heritable pulmonary arterial hypertension by impairing redox signaling, while SOD augmentation regresses experimental PAH.
Synapse has enriched 10 related papers. Consider them for comparative context: